Results 171 to 180 of about 3,133,392 (302)

Participatory co-creation of a smartphone application using Girl-Centred-Design to support adolescent girls' health: Barriers, enablers and lessons learned across six countries. [PDF]

Digit Health
Benson J, Lakeberg M, Palmer T, Brand T, Zeeb H.   +4 more
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Systematic review of barriers to and enablers of tuberculosis diagnosis, notification, and intervention for designing customised intervention package to minimise 'missing millions' in tribal communities of India. [PDF]

J Glob Health
Satav A, Raje D, Dani V, Munje R, Kumbhare S, Zodpey S, Shelgaonkar M, Fernandes G, Pinnock H, Stagg HR, Nair H.   +10 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Correction: Organisational kindness and compassion: what are the barriers, enablers and outcomes for clients and stakeholders? [PDF]

PLoS One
PLOS One Staff.
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Transfer of clinical debriefing from simulation to practice: exploring the barriers and enablers. [PDF]

Adv Simul (Lond)
Dewdney CJ, Waite SR, Ralston K, Phillips EC, Mellanby E, Tallentire VR.   +5 more
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Enablers and barriers for scaling up non-communicable disease interventions across diverse global health contexts: a qualitative study using the Consolidated Framework for Implementation Research. [PDF]

BMJ Open
Pardoel Z, Folkertsma I, Ramani-Chander A, Thrift AG, Joshi R, Bandurek I, van Olmen J, Shrestha A, Rawal LB, Wouters E, Maharani A, Delobelle P, Liu H, Theilmann M, Webster J, Sujarwoto S, Siddiqi K, Probandari A, Widyaningsih V, Miranda J, Zhang P, Stehr L, Hirschhorn LR, Koot J, Alma M.   +24 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source